PMCF study to observe the routine application of Ostenil® Mini in the treatment of pain and restricted mobility in degenerative and traumatic changes of the CMC joint.

Inclusion Criteria:

• Subjects ≥ 18 years of age and in good general health condition
• Signed informed consent
• Existing Ostenil® Mini recommendation for the treatment of rhizarthrosis

Exclusion Criteria:

• Known hypersensitivity to one of the Ostenil® Mini components
• Known pregnancy or lactating females
• Presence of coagulation disorder
• Subjects not capable of contracting and of understanding the nature, risks, significance and implications of the clinical investigation and unable to form a rational intention in the light of these facts
• Subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and / or non completion of the study according to investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)

Adult Patients with Rhizarthrosis and a Recommendation for Treatment with Ostenil® Mini.